Trial Evaluating Ravulizumab for Amyotrophic Lateral Sclerosis Discontinued
Following a prespecified interim analysis, the decision to halt the study was made based on the recommendation from the Independent Data Monitoring Committee.
Amyotrophic Lateral Sclerosis
Pridopidine Granted Orphan Drug Status for Amyotrophic Lateral Sclerosis
Pridopidine is an investigational oral drug that binds and activates the sigma-1 receptor, a protein that is highly expressed in the brain.
Exservan Now Available for Amyotrophic Lateral Sclerosis
According to the CDC, more than a thousand cases of myocarditis and pericarditis following mRNA COVID-19 vaccination have been reported to the Vaccine Adverse Event Reporting System since April 2021.
Trehalose Designated Orphan Drug for ALS
SLS-005 contains the active ingredient trehalose, a low molecular weight disaccharide that crosses the blood brain barrier, stabilizes proteins and activates autophagy.
Investigational Drug May Prolong Survival in Patients With ALS
Median survival 6.5 months longer with initiation of PB-TURSO treatment compared with placebo.
Sodium Phenylbutyrate-Taurursodiol Promising for ALS
Slower functional decline seen with active drug versus placebo through 24 weeks
FDA Grants Fast Track Status to Arimoclomol for ALS
The FDA has granted Fast Track designation to arimoclomol (Orphazyme A/S) for the treatment of amyotrophic lateral sclerosis.
Study Investigating Acthar Gel in the Treatment of ALS Discontinued
Mallinckrodt has permanently discontinued the phase 2b PENNANT trial investigating Acthar Gel (repository corticotrophin) for the treatment of amyotrophic lateral sclerosis (ALS). The study’s independent Data and Safety Monitoring Board (DSMB) recommended the trial be halted after observing a higher rate of pneumonia occurrence in Acthar-treated patients compared with those who received placebo. In addition,…
FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
The FDA approval was supported by data from bioavailability studies comparing riluzole tablets and Tiglutik oral suspension.
Radicava Now Available for the Treatment of ALS
Radicava is supplied as a 30mg/100mL solution for intravenous infusion in single-dose polypropylene bags.
